Consideration of Evidence on Antiemetic Drugs for Nausea and Vomiting Associated with Chemotherapy or Radiation Therapy in Adults

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  2010-07-22

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

  2010cited by this paper
• Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

  2010cited by this paper
• A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy

  2009influential reference
• Grading the Strength of a Body of Evidence When Comparing Medical Interventions

  2009cited by this paper
• Randomized, placebo‐controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting

  2008cited by this paper
• Evidence-based recommendations for cancer nausea and vomiting.

  2008cited by this paper
• Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?

  2007cited by this paper
• Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.

  2006influential reference
• Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

  2006cited by this paper
• The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.

  2004cited by this paper
• Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study

  2004cited by this paper
• Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

  2003cited by this paper
• The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

  2003influential reference
• Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines.

  2003influential reference
• Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting

  2003cited by this paper
• Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting

  2003influential reference
• Quantifying heterogeneity in a meta‐analysis

  2002influential reference
• Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

  2001cited by this paper
• Forest plots: trying to see the wood and the trees

  2001cited by this paper
• Current methods of the US Preventive Services Task Force: a review of the process.

  2001cited by this paper
• Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.

  2000cited by this paper
• Methods for Meta-Analysis in Medical Research

  2000cited by this paper
• Randomized, Multicenter Comparison of Oral Granisetron and Oral Ondansetron for Emetogenic Chemotherapy

  2000cited by this paper
• Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.

  2000cited by this paper
• A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation.

  1996cited by this paper
• Prognostic factors influencing cisplatin‐induced emesis. Definition and validation of a predictive logistic model

  1989cited by this paper

• Efficacy of press needle treatment in reducing chemotherapy-induced nausea, vomiting, and retching gastrointestinal cancer patients: A randomized controlled trial

  2023cites this paper
• Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial

  2022cites this paper
• ADHERENCE TO ANTIEMESIS GUIDELINES IN A DAY CARE CHEMOTHERAPY UNIT: EXPERIENCE FROM A TERTIARY CARE CENTRE

  2019cites this paper
• Adding Olanzapine to Three Drugs Anti Emetic Regimen: Is it Time to Jump the Gun?

  2018cites this paper
• Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?

  2015cites this paper
• Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies.

  2013cites this paper